drugset / Trial / NCT00977132

Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome

NCT00977132

Phase 2 Terminated 23 enrolled Heinrich-Heine University, Duesseldorf
NaSingle-groupOpen-labelTreatment

Summary

As part of a palliative therapy concept, feasibility, toxicity, and effectiveness of treatment with the combination of Valproic acid and lenalidomide in Myelodysplastic Syndrome patients with a favorable risk profile will be investigated.

Timeline

Start
2009-10
Primary completion
2013-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 5 mg Oral
Subject Valproic Acid Small molecule 500 mg